Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia
In September 2017, the US FDA announced re-approval of gemtuzumab ozogamicin (GO), a
CD33-targeting immunoconjugate, for treatment of newly diagnosed and relapsed/refractory …
CD33-targeting immunoconjugate, for treatment of newly diagnosed and relapsed/refractory …
Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults
BH Goldenson, AM Goodman… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction Treatment of acute myeloid leukemia (AML) has changed dramatically in the
past ten years with the approval of targeted agents, the first of which was the anti-CD33 …
past ten years with the approval of targeted agents, the first of which was the anti-CD33 …
Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
After being in the therapeutic wilderness for several decades, acute myeloid leukemia has
been recently thrust into the limelight with a series of drug approvals. Technical refinements …
been recently thrust into the limelight with a series of drug approvals. Technical refinements …
[HTML][HTML] Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin
AJ Cowan, GS Laszlo, EH Estey… - Frontiers in bioscience …, 2013 - ncbi.nlm.nih.gov
Antibodies have created high expectations for effective yet tolerated therapeutics in acute
myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation …
myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation …
The return of gemtuzumab ozogamicin: A humanized anti-CD33 monoclonal antibody–drug conjugate for the treatment of newly diagnosed acute myeloid leukemia
PC Egan, JL Reagan - OncoTargets and therapy, 2018 - Taylor & Francis
Through the years gemtuzumab ozogamicin (GO) has moved from a panacea in the
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …
FDA approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia
EY Jen, CW Ko, JE Lee, PL Del Valle, A Aydanian… - Clinical cancer …, 2018 - AACR
Abstract On September 1, 2017, the FDA granted approval for gemtuzumab ozogamicin
(Mylotarg; Pfizer Inc.) in combination with daunorubicin and cytarabine and as a …
(Mylotarg; Pfizer Inc.) in combination with daunorubicin and cytarabine and as a …
Gemtuzumab ozogamicin for acute myeloid leukemia
FR Appelbaum, ID Bernstein - Blood, The Journal of the …, 2017 - ashpublications.org
Abstract On 1 September 2017, the US Food and Drug Administration (FDA) approved
gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33+ …
gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33+ …
Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia
R Stasi - Expert opinion on biological therapy, 2008 - Taylor & Francis
Background: Gemtuzumab ozogamicin consists of a semisynthetic derivative of
calicheamicin, a potent cytotoxic antibiotic, linked to a humanized anti-CD33 monoclonal …
calicheamicin, a potent cytotoxic antibiotic, linked to a humanized anti-CD33 monoclonal …
FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33‐positive acute myeloid leukemia
KJ Norsworthy, CW Ko, JE Lee, J Liu, CS John… - The …, 2018 - academic.oup.com
Abstract On September 2, 2017, the US Food and Drug Administration approved
gemtuzumab ozogamicin (GO; Mylotarg; Pfizer, New York City, NY) for treatment of relapsed …
gemtuzumab ozogamicin (GO; Mylotarg; Pfizer, New York City, NY) for treatment of relapsed …
Therapeutic targeting of acute myeloid leukemia by gemtuzumab ozogamicin
M Gottardi, G Simonetti, A Sperotto, D Nappi… - Cancers, 2021 - mdpi.com
Simple Summary Gemtuzumab Ozogamicin (GO) is a drug approved for the treatment of
acute myeloid leukemia (AML). It targets leukemic cells that express the CD33 molecule on …
acute myeloid leukemia (AML). It targets leukemic cells that express the CD33 molecule on …